epitope anti-folate receptor vaccine (FRa), in combination with Astra Zeneca durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer. In June 2016, Foundation Medicine, Inc. and AstraZeneca announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for Lynparza(olaparib) to support its global development program. The companion diagnostic would enable physicians to identify those patients most likely to benefit from AstraZeneca's poly ADP-ribose polymerase (PARP) inhibitor. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.
astrazeneca plc-spons adr (AZN:New York)
2 Kingdom Street
London, W2 6BD
Phone: 44 20 7604 8000
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for AZN.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.